| Non-Small Cell Lung Carcinoma
Cyramza vs Krazati
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Cyramza vs Krazati with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKrazati has a higher rate of injection site reactions vs Cyramza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Krazati but not Cyramza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cyramza
Krazati
At A Glance
IV infusion
Every 2 weeks
VEGFR2 antagonist
Oral
Twice daily
KRAS G12C inhibitor
Indications
- Gastric Adenocarcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Liver carcinoma
- Non-Small Cell Lung Carcinoma
- Colorectal Neoplasms
Dosing
Gastric Adenocarcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent or in combination with weekly paclitaxel.
Non-Small Cell Lung Carcinoma (EGFR exon 19/21, first-line) 10 mg/kg every 2 weeks by IV infusion in combination with erlotinib.
Non-Small Cell Lung Carcinoma (post-platinum progression) 10 mg/kg by IV infusion on Day 1 of a 21-day cycle in combination with docetaxel.
Metastasis from malignant neoplasm of colon and/or rectum 8 mg/kg every 2 weeks by IV infusion prior to FOLFIRI.
Liver carcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent.
Non-Small Cell Lung Carcinoma 600 mg orally twice daily as a single agent until disease progression or unacceptable toxicity; swallow tablets whole with or without food.
Colorectal Neoplasms 600 mg orally twice daily in combination with cetuximab until disease progression or unacceptable toxicity; swallow tablets whole with or without food.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Hypertension, fatigue/asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, stomatitis, proteinuria, thrombocytopenia, decreased appetite, nausea.
Serious Febrile neutropenia, pneumonia, hemorrhage, gastrointestinal perforation, arterial thromboembolic events, impaired wound healing, posterior reversible encephalopathy syndrome, proteinuria including nephrotic syndrome, infusion-related reactions, sepsis.
Postmarketing Thrombotic microangiopathy, hemangioma, dysphonia, arterial aneurysms/dissections/rupture, heart failure.
Most common (>=25%) nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, decreased appetite
Serious pneumonia, dyspnea, renal impairment, sepsis, respiratory failure, pleural effusion, anemia, cardiac failure
Pharmacology
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D, inhibiting ligand-stimulated activation of VEGFR2 and thereby inhibiting endothelial cell proliferation, migration, and angiogenesis.
Adagrasib is an irreversible KRAS G12C inhibitor that covalently binds to the mutant cysteine residue, locking KRAS G12C in its inactive GDP-bound state and preventing downstream signaling without affecting wild-type KRAS.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cyramza
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Krazati
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Cyramza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Krazati
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Cyramza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Krazati
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cyramza.
No savings programs available for Krazati.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyramzaView full Cyramza profile
KrazatiView full Krazati profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.